Antihypertensive effect of prizidilol.
Prizidilol (SK&F 92657), a new combined precapillary vasodilator and nonselective beta-adrenoceptor blocking drug, was given to 19 patients with essential hypertension. Following placebo (4 weeks, single-blind), patients were randomly assigned to receive either 200 or 400 mg prizidilol once daily. Blood pressure and heart rate were measured every second week for 12 weeks, 24 h after drug administration. In patients with inadequate blood pressure response the dosage was then increased to 400 mg twice daily for 4 additional weeks. In this study prizidilol given once daily did not effectively reduce systolic blood pressure for 24 h, but when given twice daily (400 mg X 2), it had an effective antihypertensive effect. Plasma concentrations of prizidilol were generally low 24 h after drug intake, and there was no significant correlation between blood pressure reduction and plasma concentration.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D011724:Pyridazines; D014665:Vasodilator Agents; C024293:prizidilol